荐读： 2025募资市场年度观察：一年聊过239家LP的真实感受 2月4日，上海医药集团股份有限公司（以下简称"公司"、"本公司"或"上海医药" ）发布公告， 公司拟通过产权交易所以公开挂牌方式转让所持参股子公司中美上海施贵宝制药有限公司（以下简 称"中美施贵宝"或 "标的公司" ）30%股权，挂牌转让价格（下称"挂牌底价" ）不低于人民币 10.23亿元。 公告指出，百时美施贵宝（中国）投资有限公司拟对外出售其持有的中美施贵宝60%股权，经多 轮竞标与谈判，潜在收购方于2025年6月提交确认性报价，拟以4.8亿美元的等值人民币收购中美 施贵宝的100%股权。其中，上海医药持有30%股权对应价格1.44亿美元。以评估基准日（2025 年9月 30日）中国人民银行发布的人民币对美元汇率中间价7.1055为准，拟定挂牌底价为人民币 102,319.2 万元（需完成相关国有评估管理程序） 此次挂牌底价系参照潜在收购方拟收购中美施贵宝 100%股权的市场化报价，按持股比例折算确 定，高于交易标的的评估值，且最终转让价格以公开挂牌成交结果为准。 来源：上海医药股份有限公司 每日｜荐读 热文： 谁押中了沐曦股份？ 荐读： ...

长江商报消息 ●长江商报记者 沈右荣 追求资产价值最大化，上海医药（601607.SH）拟出售资产。 2月4日晚，上海医药公告，公司拟通过公开挂牌方式转让中美上海施贵宝制药有限公司（简称"中美施 贵宝"）30%股权，转让价格不低于10.23亿元。 2025年，中美施贵宝60%股权对外出售，潜在收购方提交的中美施贵宝100%股权的报价为4.8亿美元。 上海医药公告称，在市场化报价下实现股权退出更能够实现资产价值最大化，遂寻求转让所持标的公司 股权。 上海医药主营业务覆盖医药工业和医药商业。近年来，公司加速创新转型，通过打造具有优势的药物研 发、临床研究、中试生产、产业化制造及营销推广的工业体系，提升综合竞争力。 2021年至2024年，上海医药研发投入合计超过百亿元，2025年前三季度，研发投入逾15亿元。 上海医药取得了不菲的研发成果。2025年12月，公司自研新药SPH3127片高血压适应症已正式获批上 市，一种渐冻症新药已启动III期临床试验。 上海医药盈利能力较强。2025年前三季度，公司实现的归母净利润超过50亿元。 超10亿转让或获利7.67亿 上海医药选择出手，退出中美施贵宝股东之列。 1982年 ...

Core Viewpoint - The restructuring of China-U.S. Shanghai Bristol-Myers Squibb Co., a joint venture with over 40 years of history, is underway as Shanghai Pharmaceuticals plans to sell its 30% stake, marking a significant shift in ownership amid declining performance [1][6]. Group 1: Share Transfer Details - Shanghai Pharmaceuticals intends to publicly auction its 30% stake in China-U.S. Bristol-Myers Squibb with a minimum price of RMB 1.023 billion, following the sale of a 60% stake by Bristol-Myers Squibb to Hillhouse Capital [3][4]. - After the transfer, Shanghai Pharmaceuticals will no longer hold any shares in China-U.S. Bristol-Myers Squibb, aiming to optimize its investment structure and maximize asset value [3][4]. Group 2: Financial Performance - China-U.S. Bristol-Myers Squibb's revenue has plummeted over 60% from a peak of RMB 4.724 billion in 2016 to an estimated RMB 1.795 billion in 2024, with a net profit of only RMB 248 million [6][7]. - The company reported revenue of RMB 1.096 billion and a net profit of RMB 87.12 million for the first three quarters of 2025, indicating ongoing financial struggles [6]. Group 3: Market Dynamics and Strategic Choices - The decline in performance is attributed to the expiration of patents for key original drugs and the inability to secure competitive new drug pipelines from foreign partners, leading to a lack of growth drivers [7]. - The decision by Shanghai Pharmaceuticals to divest is seen as a rational choice to recover over RMB 1 billion in capital, aligning with the need to focus on high-growth areas and optimize resource allocation [7][8]. Group 4: Industry Trends - China-U.S. Bristol-Myers Squibb is not the only joint venture undergoing restructuring; other early foreign-invested pharmaceutical companies like Xi'an Janssen and China-SK have also made similar adjustments [8][9]. - The exit of these joint ventures reflects a broader transformation in the Chinese pharmaceutical landscape, driven by policy changes, strategic refocusing by multinational companies, and a shift in market competition dynamics [10].

Core Viewpoint - Shanghai Pharmaceuticals announced the intention to publicly transfer 30% of its stake in China-U.S. Shanghai Bristol-Myers Squibb Pharmaceutical Co., Ltd. (hereinafter referred to as "China-U.S. Bristol-Myers Squibb") through a property rights transaction, with a minimum listing price of 1.023 billion yuan [1][4]. Group 1: Company Overview - China-U.S. Bristol-Myers Squibb, established in 1982, is a well-known Sino-U.S. joint venture pharmaceutical company with a registered capital of 18.44 million USD. The shareholding structure includes Bristol-Myers Squibb (China) Investment Co., Ltd. holding 60%, Shanghai Pharmaceuticals holding 30%, and China National Pharmaceutical Group Asset Management Co., Ltd. holding 10% [2][5]. - The company has launched nearly 30 products in China, covering prescription drugs for cardiovascular, metabolic, and antibiotic treatments, as well as over-the-counter products like pain relievers and multivitamins [2][5]. Group 2: Financial Performance - In 2016, China-U.S. Bristol-Myers Squibb achieved a historical peak with revenues of 4.724 billion yuan and a net profit of 622 million yuan. However, the company's operational performance has declined since then [2][5]. - For the year 2024, the company reported revenues of 1.795 billion yuan and a net profit of 248 million yuan. In the first three quarters of 2025, revenues further declined to 1.096 billion yuan, with a net profit of only 87.11 million yuan [2][5][7]. Group 3: Share Transfer and Market Strategy - In September 2025, it was reported that Bristol-Myers Squibb signed an agreement to sell its 60% stake in China-U.S. Bristol-Myers Squibb to an affiliate of Hillhouse Capital. This move is aimed at allowing Bristol-Myers Squibb to focus on key growth areas while leveraging local manufacturing and market advantages [3][6]. - The transfer of 30% of the stake by Shanghai Pharmaceuticals indicates a potential comprehensive adjustment in the shareholding structure of this over 40-year-old joint venture pharmaceutical company. The minimum price for the stake transfer is set at 1.023192 billion yuan, reflecting a strategic decision to maximize asset value and protect the interests of all shareholders, especially minority shareholders [3][6].

Core Viewpoint - The restructuring of China-U.S. Bristol-Myers Squibb (BMS) marks a significant shift in the landscape of joint ventures in the pharmaceutical industry, driven by declining performance and strategic realignment [1][10]. Group 1: Share Transfer Details - Shanghai Pharmaceuticals plans to publicly transfer its 30% stake in China-U.S. Bristol-Myers Squibb through a property trading platform, with a minimum listing price of RMB 1.023 billion [1][5]. - BMS previously sold its 60% stake in the joint venture to Hillhouse Capital, with the transaction expected to complete in early 2026 [5][6]. - The transfer of shares is part of a broader trend where early joint ventures in the pharmaceutical sector are undergoing ownership changes and brand integrations [1][10]. Group 2: Financial Performance - China-U.S. Bristol-Myers Squibb's revenue has declined over 60% from its peak of nearly RMB 5 billion in 2016 to an estimated RMB 1.795 billion in 2024 [1][8]. - The company reported a net profit of only RMB 248 million in 2024, with revenues of RMB 1.096 billion in the first three quarters of 2025 [8][9]. - The decline in performance is attributed to market pressures and an aging product line, with key original drugs losing patent protection and facing competition from low-cost generics [9][11]. Group 3: Strategic Implications - The decision by Shanghai Pharmaceuticals to divest its stake is seen as a rational choice to maximize asset value and protect shareholder interests, particularly for minority shareholders [9][10]. - The shift in focus from mature drug businesses to innovative drug development aligns with the strategic direction of Shanghai Pharmaceuticals [9][11]. - The exit of early joint venture giants from the market reflects a significant transformation in the Chinese pharmaceutical landscape, driven by policy changes and evolving market dynamics [10][11].

Group 1 - The company plans to transfer 30% equity stake in its subsidiary, China-America Shanghai Bristol-Myers Squibb Pharmaceutical Co., Ltd., through public listing at a minimum price of 1.023 billion yuan [1] - The purpose of the transaction is to optimize the investment structure and maximize asset value, with the final price determined by the public listing results [1][2] - The current ownership structure of China-America Bristol-Myers Squibb includes 60% held by Bristol-Myers Squibb (China) Investment Co., Ltd., 30% by the company, and 10% by China National Pharmaceutical Group Asset Management Co., Ltd. [1] Group 2 - Bristol-Myers Squibb (China) Investment Co., Ltd. intends to sell its 60% stake in China-America Bristol-Myers Squibb, with a potential buyer expected to submit a confirmation bid by June 2025 for a total acquisition price of 480 million USD, equivalent to 1.44 billion yuan for the company's 30% stake [1] - The company believes that achieving an exit through market-based pricing will better maximize asset value and protect the interests of all shareholders, especially minority shareholders [2]

Core Viewpoint - Shanghai Pharmaceuticals plans to transfer its 30% stake in China Bristol-Myers Squibb through a public listing, with a minimum transfer price of 1.023 billion yuan [1] Group 1: Stake Transfer Details - The current ownership of China Bristol-Myers Squibb consists of three parties: 60% by Bristol-Myers Squibb (China) Investment Co., Ltd., 30% by Shanghai Pharmaceuticals, and 10% by China National Pharmaceutical Group Asset Management Co., Ltd. [1] - If the transfer is successful, Shanghai Pharmaceuticals will no longer hold any stake in China Bristol-Myers Squibb [1] - Bristol-Myers Squibb is also planning to transfer its 60% stake, with potential buyers expected to submit confirmation bids by June 2025, valuing the entire company at 480 million USD [1] Group 2: Financial Performance of China Bristol-Myers Squibb - The company has experienced a decline in performance due to centralized procurement and competition, with revenues of 1.795 billion yuan and a net profit of 248 million yuan in 2024 [2] - For the first three quarters of 2025, revenues dropped to 1.096 billion yuan and net profit to approximately 87.12 million yuan, significantly lower than the peak revenues of 4.724 billion yuan and net profits of 622 million yuan in 2016 [2] Group 3: Shanghai Pharmaceuticals' Strategic Moves - Shanghai Pharmaceuticals has been optimizing its assets, having invested nearly 1 billion yuan to gain further control of Huang Pharmaceutical last year, acquiring several traditional Chinese medicine products [2] - The company has also made acquisitions of multiple DTP pharmacy enterprises through its subsidiary, Shanghai Pharmaceuticals Cloud Health platform [2] - In terms of R&D, Shanghai Pharmaceuticals has increased its investment, with a total of 1.729 billion yuan in R&D for the first three quarters of 2025, and currently has 57 new drug pipelines, including 45 innovative drugs [2] Group 4: Financial Performance of Shanghai Pharmaceuticals - For the first three quarters of 2025, Shanghai Pharmaceuticals reported revenues of 215.072 billion yuan, a year-on-year increase of 2.60%, and a net profit attributable to shareholders of 5.147 billion yuan, up 26.96% [2] - However, the net profit after deducting losses was 3.979 billion yuan, reflecting a year-on-year decrease of 1.85% [2]

Market Overview - AMD's overnight drop of 17% triggered a significant decline in chip stocks, leading to a 1.95% drop in the Chinese concept index, which negatively impacted the Hong Kong stock market [1] - The Hang Seng Index fell by 340.88 points, or 1.27%, to 26,506.44 points, while the Hang Seng Tech Index decreased by 62.30 points, or 1.16%, to 5,304.14 points [1] - Major tech stocks like Tencent and Alibaba saw declines of nearly 3% and 2.5%, respectively, with Tencent's market value dropping below 500 billion [1] Company Performance - Xinda Biopharmaceuticals (01801.HK) projected total product revenue of approximately RMB 11.9 billion for 2025, reflecting a year-on-year growth of about 45% [2] - Lee & Man Paper Manufacturing (02314.HK) expects profits for 2025 to be between HKD 1.88 billion and HKD 2.00 billion, indicating a year-on-year increase of 38% to 47% [2] - ZTO Express (02057.HK) anticipates total revenue of RMB 48.5 billion to RMB 50 billion for 2025, representing a year-on-year growth of approximately 9.5% to 12.9% [2] - China Resources Cement (01313.HK) forecasts a year-on-year profit increase of about 115% to 135% for 2025, driven by reduced costs and impairment losses [2] Corporate Actions - Goldin Properties (00535.HK) reported a January contract sales total of approximately RMB 239 million, a year-on-year decrease of 61.82% [3] - Fosun International (00656.HK) plans to subscribe for additional registered capital of RMB 105 million in Shangmeng Technology, acquiring a 51.0879% stake post-increase [3] - Shanghai Pharmaceuticals (02607.HK) intends to publicly transfer its 30% stake in Bristol-Myers Squibb, with a minimum listing price of approximately RMB 1.023 billion [3] - China Coalbed Methane (08270.HK) completed the sale of 100% equity in Shanxi Qingshui Shuntai Energy Development [4] Investment Trends - The active repurchase of shares continues, with Kingsoft (03888.HK) repurchasing 1.0886 million shares for approximately HKD 29.99 million [9] - Xiaomi Group (01810.HK) repurchased 4.3 million shares for a total of HKD 146 million [10] - Kingdee International (00268.HK) repurchased 1 million shares for approximately HKD 11.1 million [11] Market Outlook - Guoyuan International's report suggests that the Hong Kong stock market may experience short-term volatility due to external factors, but maintains a positive long-term outlook [12] - CITIC Securities highlights the potential for new investment opportunities in emerging markets, despite risks from rising oil prices and long-term bond yields [12] - Galaxy Securities recommends focusing on technology, energy, precious metals, and consumer sectors for potential rebounds [13]

Group 1 - Shanghai Pharmaceuticals plans to transfer 30% equity stake in China and America Bristol-Myers Squibb for no less than 1.023 billion yuan, aiming to optimize investment structure and achieve asset appreciation [1] - The net profit of the target company for the first three quarters of 2025 was 87.11 million yuan, and the transaction is not expected to have a significant impact, although uncertainties exist regarding the buyer [1] Group 2 - Pianzaihuang's controlling shareholder, Jiulongjiang Group, has received a loan commitment from Industrial and Commercial Bank of China for up to 450 million yuan to support the purchase of additional shares [2] - The controlling shareholder plans to use additional self-funding of 300 million to 500 million yuan for the share acquisition, reflecting confidence in the company's value [2] Group 3 - Qizheng Tibetan Medicine's subsidiary has received a registration certificate for the "Cui Tang Granules" from the Macau government, which is a traditional Chinese medicine for respiratory issues [3] - The approval is expected to help expand the company's presence in overseas markets, although it is not anticipated to have a significant impact on recent performance [3] Group 4 - Zhifei Biological's subsidiary has received approval for clinical trials of a freeze-dried varicella inactivated vaccine, which aims to prevent chickenpox and shingles [4] - The vaccine utilizes self-developed technology and fills a gap in the domestic inactivated vaccine market, but is not expected to have a major short-term impact on performance [4] Group 5 - Innovent Biologics forecasts total product revenue of approximately 11.9 billion yuan for 2025, marking a year-on-year growth of about 45% [5] - The company achieved approximately 3.3 billion yuan in total product revenue in the fourth quarter of 2025, with a year-on-year increase of over 60%, driven by steady growth in 13 oncology products and the release of 3 chronic disease medications [5]

Core Viewpoint - Shanghai Pharmaceuticals plans to transfer 30% equity stake in its subsidiary, China Medical Shanghai Bristol-Myers Squibb Pharmaceutical Co., Ltd. (referred to as "China Medical Bristol-Myers Squibb"), through a public listing with a minimum transfer price of 1.023 billion yuan [1][2] Group 1: Transaction Details - The transfer price is based on the previous equity disposal plan by Bristol-Myers Squibb, which aimed to sell its 60% stake in China Medical Bristol-Myers Squibb for approximately 480 million USD, equating to 1.44 billion USD for Shanghai Pharmaceuticals' 30% stake [1] - The transaction will result in Shanghai Pharmaceuticals no longer holding any equity in China Medical Bristol-Myers Squibb if completed successfully [1] Group 2: Company Financials - China Medical Bristol-Myers Squibb, established in 1982, has a registered capital of 18.44 million USD and operates in the pharmaceutical manufacturing sector [2] - For the fiscal year 2024 and the first three quarters of 2025, the company reported revenues of 1.795 billion yuan and 1.096 billion yuan, with net profits of 248 million yuan and 87.11 million yuan, respectively [2] - As of September 30, 2025, the total assets of China Medical Bristol-Myers Squibb amounted to 1.262 billion yuan, with net assets of 797 million yuan [2] Group 3: Strategic Implications - The transaction is expected to maximize asset value and protect the interests of all shareholders, particularly minority shareholders [1] - Shanghai Pharmaceuticals asserts that this transaction will not significantly impact its normal operations and financial status, while also optimizing its investment structure [2]